SG11201607298QA - Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer - Google Patents

Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer

Info

Publication number
SG11201607298QA
SG11201607298QA SG11201607298QA SG11201607298QA SG11201607298QA SG 11201607298Q A SG11201607298Q A SG 11201607298QA SG 11201607298Q A SG11201607298Q A SG 11201607298QA SG 11201607298Q A SG11201607298Q A SG 11201607298QA SG 11201607298Q A SG11201607298Q A SG 11201607298QA
Authority
SG
Singapore
Prior art keywords
eribulin
cancer
treatment
combination therapy
mtor inhibitors
Prior art date
Application number
SG11201607298QA
Other languages
English (en)
Inventor
Yasuhiro Funahashi
Toshimitsu Uenaka
Bruce A Littlefield
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11201607298QA publication Critical patent/SG11201607298QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201607298QA 2014-03-03 2015-03-02 Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer SG11201607298QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461947398P 2014-03-03 2014-03-03
PCT/US2015/018335 WO2015134399A1 (en) 2014-03-03 2015-03-02 Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
SG11201607298QA true SG11201607298QA (en) 2016-09-29

Family

ID=54055761

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607298QA SG11201607298QA (en) 2014-03-03 2015-03-02 Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer

Country Status (11)

Country Link
US (1) US20170071903A1 (zh)
EP (1) EP3113775A4 (zh)
JP (1) JP2017507151A (zh)
KR (1) KR20160135230A (zh)
CN (1) CN106029070A (zh)
AU (1) AU2015225436A1 (zh)
CA (1) CA2940983A1 (zh)
IL (1) IL247586A0 (zh)
RU (1) RU2016136504A (zh)
SG (1) SG11201607298QA (zh)
WO (1) WO2015134399A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3587408A1 (en) 2004-06-03 2020-01-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin b
ME02518B (me) 2009-03-30 2017-02-20 Eisai R&D Man Co Ltd Smeša lipozoma
KR102265952B1 (ko) 2013-06-26 2021-06-16 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
JP7015237B2 (ja) * 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
CN113271977A (zh) * 2018-11-09 2021-08-17 G1治疗公司 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004163B1 (en) * 2006-04-05 2014-09-17 Novartis Pharma AG Combination of everolimus and vinorelbine
JP6141016B2 (ja) * 2009-08-27 2017-06-07 バイオノミックス リミテッド 増殖性疾患の治療のための併用療法
JP2014508165A (ja) * 2011-03-02 2014-04-03 モルフォテック、インク． 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与
BR112014024494A2 (pt) * 2012-04-02 2017-08-08 Merrimack Pharmaceuticals Inc dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos

Also Published As

Publication number Publication date
WO2015134399A1 (en) 2015-09-11
AU2015225436A1 (en) 2016-09-08
EP3113775A1 (en) 2017-01-11
IL247586A0 (en) 2016-11-30
CN106029070A (zh) 2016-10-12
EP3113775A4 (en) 2017-08-23
JP2017507151A (ja) 2017-03-16
RU2016136504A3 (zh) 2018-10-25
KR20160135230A (ko) 2016-11-25
RU2016136504A (ru) 2018-04-03
CA2940983A1 (en) 2015-09-11
US20170071903A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
HK1247129A1 (zh) 治療癌症的聯合療法
HK1251475A1 (zh) 用於癌症治療的聯合療法
IL242386B (en) Use of Aribolin and Lavetinib as a combination therapy for cancer treatment
HUE057061T2 (hu) Kombinációs terápia rák kezelésére
IL276733A (en) Use of Aribolin in cancer treatment
HRP20190888T8 (hr) Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
IL247586A0 (en) Use of Aribolin and mtor inhibitors as a combined treatment for cancer
EP3226901A4 (en) Combination therapy for treatment of cancer
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
EP3185884A4 (en) Combination therapy for treatment of cancer
IL254842A0 (en) Therapeutic preparations and methods for use in cancer treatment
IL258494A (en) Rational combined therapy for cancer treatment
EP3440052C0 (en) COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
GB201418640D0 (en) Agents and methods for treatment of cancer
ZA201403006B (en) Composition for use in treatment of cancer